Boston to distribute CorTrak's products:
This article was originally published in Clinica
Boston Scientific will exclusively distribute the coronary iontophoresis drug delivery products which are being developed by CorTrak Medical. Boston has also made an unspecified equity investment in CorTrak, which is based in Minneapolis. The CorTrak system is in pre-clinical studies and uses a catheter and an electric field to transport drugs through difficult tissue barriers and into cells. Initially, the company will focus on treating and preventing problems associated with coronary angioplasty.
You may also be interested in...
The addition of the question “Was this device serviced by a third party servicer?” to adverse event reports filed through the US FDA’s electronic Medical Device Reporting system could prove helpful for the agency and device makers, experts tell Medtech Insight. Industry has long complained about poor work performed by servicers – and loudly groused that they’re not regulated.
Attorneys tell Medtech Insight a recent proposal to review regulations every 10 years could lift some burdens from the medical device industry, but warned that the full effects may not be seen for some time.
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.